Instead of targeting the final protein, Remix develops small molecules that intervene during pre-mRNA processing. This novel approach allows them to inhibit historically difficult drug targets like MYB, a transcription factor with no obvious binding sites, by preventing the disease-driving protein from ever being made.
Remix Therapeutics leveraged compelling Phase 1 data in a rare cancer with no approved treatments to accelerate its corporate strategy. Achieving a 43% overall response rate, far exceeding the 15% from prior therapies, provided the clinical validation necessary to pursue a reverse merger and go public.
Remix Therapeutics is going public by merging with an existing public company, Passage Bio, and raising a concurrent $100M financing. This reverse merger strategy provides a faster and potentially less volatile route to the stock exchange compared to a traditional IPO, allowing them to quickly capitalize on positive clinical momentum.
Remix Therapeutics is using the clinical success of its first drug (targeting MYB) to validate its entire RNA modulation platform. This initial proof-of-concept provides strong rationale and investor confidence to pursue even more challenging and significant oncogenes like MYC, one of oncology's most sought-after targets.